Figure 3
From: An epigenetic vaccine model active in the prevention and treatment of melanoma
TSA treatment converts B16 melanoma cells to APCs. A) In vitro antigen presentation by TSA-treated (500 nM for 48 h) B16 cells. Purified T cells from OT-II mice were cultured with antigen-pulsed (ova-peptide322–338 or control peptide), irradiated B16 cells (TSA-treated or untreated) and splenocytes (from OT-II mice as control APCs) in a standard ELISpot assay to measure IFN-γ-secreting cells. B) Eight weeks after BM transplantation, control [B6-C] and MHC double knockout [DKO-C] chimeras were inoculated s.c. with TSA-treated B16 (1 × 105 cells) in the trunk and tumor-free survival was recorded. Control groups of B6-C and DKO-C chimeras were injected with untreated B16 cells. The survival curve for these two groups were coincident; therefore a representative plot [chimeras, untreated B16] showing the tumor-free survival of these controls is presented. Results from two independent experiments (four chimeras/group/experiment) are presented in this figure.